SCHEMBL16288295

SCHEMBL16288295

CCOC(=O)[C@H](CS)NC(=O)CCC(NC(=O)OC(C)(C)C)C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
HTT P42858 1/20 0.51
NOD1 Q9Y239 4/20 0.47
ACE P12821 1/20 0.46
KMT2A Q03164 2/20 0.45
POLB P06746 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
ALDH1A1 P00352 3/20 0.43
MAPT P10636 3/20 0.43
KDM4E B2RXH2 1/20 0.42
GAA P10253 1/20 0.42
PKM P14618 1/20 0.42
HPGD P15428 1/20 0.42
ALOX12 P18054 1/20 0.42
CTSS P25774 2/20 0.41
CTSK P43235 2/20 0.41
FOLH1 Q04609 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16288297 1.00 CYP1A2 (0.51) CYP1A2CYP2C9CYP2C19HTTNOD1
SCHEMBL16288581 0.88 CYP1A2 (0.50) CYP1A2CYP2C9CYP2C19HTTACE
SCHEMBL16288582 0.88 CYP1A2 (0.50) CYP1A2CYP2C9CYP2C19HTTACE
SCHEMBL18661581 0.86 ACE (0.48) CYP1A2CYP2C9CYP2C19HTTNOD1
SCHEMBL1455923 0.85 CYP1A2 (0.61) CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2
SCHEMBL1455920 0.85 CYP1A2 (0.61) CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2
SCHEMBL16288666 0.85 CYP1A2 (0.50) CYP1A2CYP2C9CYP2C19HTTNOD1
SCHEMBL16288665 0.85 CYP1A2 (0.50) CYP1A2CYP2C9CYP2C19HTTNOD1
SCHEMBL23140735 0.84 ACE (0.51) CYP1A2CYP2C9CYP2C19HTTACE
SCHEMBL15083163 0.84 ACE (0.51) CYP1A2CYP2C9CYP2C19HTTACE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240166689-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-05-23 US disclosed
US-11891457-B2 Peptide-compound cyclization method CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-02-06 US disclosed
EP-2813512-B1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI PHARMACEUTICAL CO LTD (JP) 2021-03-31 EP disclosed
US-20210061860-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2021-03-04 US disclosed
US-20160311858-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-10-27 US disclosed
US-9409952-B2 Peptide-compound cyclization method CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-08-09 US disclosed
US-20150080549-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-03-19 US disclosed
EP-2813512-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD Chugai Seiyaku Kabushiki Kaisha (JP) 2014-12-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11891457-B2 Peptide-compound cyclization method VIP, NGLY1, GLP1R CYP1A2 4833/4885CYP2C9 4341/4885CYP2C19 3767/4885
US-20210061860-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD VIP, NGLY1, GLP1R CYP1A2 4833/4885CYP2C9 4341/4885CYP2C19 3767/4885
US-20240166689-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD VIP, NGLY1, GLP1R CYP1A2 4833/4885CYP2C9 4341/4885CYP2C19 3767/4885
US-20160311858-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD VIP, NGLY1, GLP1R CYP1A2 4833/4885CYP2C9 4341/4885CYP2C19 3767/4885
US-20150080549-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD VIP, NGLY1, GLP1R CYP1A2 4833/4885CYP2C9 4341/4885CYP2C19 3767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.